Candel Therapeutics Inc. (CADL)

Candel Therapeutics Inc (NASDAQ:CADL) announced that it has appointed Dr Bali Pulendran, a leading authority in systems immunology and vaccinology, to its Research Advisory Board. Dr Pulendran is the ...

Candel Therapeutics Inc (NASDAQ:CADL) said it has inked a five-year, $130 million term loan facility with Trinity Capital to strengthen its balance sheet and support late-stage development and potenti...

Deep Dive - Candel Therapeutics Inc

Candel Therapeutics has generated favorable phase 3 data supportive of a BLA submission in prostate cancer, but it won't come until the end of next year. In the meantime, the market appears to be anti...

Candel Therapeutics Inc (NASDAQ:CADL) said Monday that its experimental treatment CAN-2409 significantly extended the time patients lived without their prostate cancer returning, according to results ...

Candel Therapeutics' CAN-2409 shows robust, multi-cancer efficacy with significant survival gains in prostate, pancreatic, and lung cancers, plus promising early glioblastoma data. The company is fina...

Candel Therapeutics Inc (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on viral immunotherapies, announced the appointment of Dr Carl June to its Research Advisory Board. Dr June is...

Candel Therapeutics Inc (NASDAQ:CADL) CEO talked with Proactive earlier this week about the company's recent achievements in oncology drug development, with a strong focus on its gene therapy programs...

Candel Therapeutics Inc (NASDAQ:CADL) said on Thursday it plans to seek US approval for its lead cancer drug CAN-2409 in late 2026, after a key Phase 3 prostate cancer trial succeeded and the FDA gran...

Candel Therapeutics Inc (NASDAQ:CADL) announced that the European Medicines Agency (EMA) has granted Orphan Designation to its investigational immunotherapy CAN-2409 for the treatment of pancreatic ca...